Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 199 of the 200 references it cites were found in a registry or an index; 79 of the 184 sources its claims cite were checked for support.

3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip

Open access

Abstract

Decades of efforts in engineering in vitro cancer models have advanced drug discovery and the insight into cancer biology. However, the establishment of preclinical models that enable fully recapitulating the tumor microenvironment remains challenging owing to its intrinsic complexity. Recent progress in engineering techniques has allowed the development of a new generation of in vitro preclinical models that can recreate complex in vivo tumor microenvironments and accurately predict drug responses, including spheroids, organoids, and tumor-on-a-chip. These biomimetic 3D tumor models are of particular interest as they pave the way for better understanding of cancer biology and accelerating the development of new anticancer therapeutics with reducing animal use. Here, the recent advances in developing these in vitro platforms for cancer modeling and preclinical drug screening, focusing on incorporating hydrogels are reviewed to reconstitute physiologically relevant microenvironments. The combination of spheroids/organoids with microfluidic technologies is also highlighted to better mimic in vivo tumors and discuss the challenges and future directions in the clinical translation of such models for drug screening and personalized medicine.

Overview

CoChat Summary

## TL;DR

This paper is a review of 3D biomimetic in vitro cancer models—spheroids, organoids, and tumor-on-a-chip—aimed at better reconstituting the tumor microenvironment (TME) for cancer biology and drug screening. It argues that these models can better capture ECM, hypoxia, interstitial flow, and multicellular interactions than 2D culture, while highlighting challenges for clinical translation and personalized medicine.

## Key findings

  • The paper states that 2D monolayer models cannot recreate the complex tumor microenvironment, and that animal models are low throughput, time-consuming, costly, and limited by murine physiology; it notes that less than 4% of anticancer drug candidates pass clinical trials to FDA approval.
  • 3D tumor spheroids can exceed 400 µm and develop in vivo-like oxygen/nutrient gradients with a necrotic core, quiescent intermediate region, and proliferating outer shell; they also replicate cell–cell interactions and de novo ECM deposition, and are used for routine drug screening.
  • Patient-derived organoids preserve structural and functional features of in vivo tumors and, in one cited platform, supported organoid culture from over 1000 patients; organoids and organoids-on-a-chip are described as promising for predicting patient-specific drug responses.
  • Microfluidic tumor-on-a-chip systems are presented as especially useful for modeling metastasis, angiogenesis, BBB transport, and therapy response because they can control fluid flow, multiple cell types, and microenvironmental cues; one BBB nanoparticle transport platform was reported to be faster than a 2D transwell setup (5 min vs 3 h).

## Methods

  • Narrative review of recent advances in engineered 3D cancer models, organized around TME components, spheroids, organoids, and tumor-on-a-chip platforms.
  • The paper synthesizes examples from prior studies using hydrogel-based systems, microfluidic devices, 3D bioprinting, microwell arrays, and coculture models with cancer, stromal, immune, endothelial, and BBB-related cells.
  • It qualitatively compares model features and applications for cancer progression, metastasis, and anticancer drug screening rather than presenting new experimental data.

## Limitations

  • The paper states that current 3D models still have limitations before widespread use, including incomplete incorporation of tumor vasculature, limited reproducibility, difficulty with long-term culture, and lack of scalability to high-throughput screening.
  • It also states that many models do not fully capture the native TME because of nonstandardized or ill-defined matrices such as Matrigel, insufficient tissue-specific biochemical/biophysical cues, and lack of stromal or immune components.
  • Evident from the text: this is a review article, so it does not generate new primary data or directly validate the summarized platforms in a single experimental system.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/adhm.202202609

Cites

199 of 199 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Schematic overview showing the in vitro strategies to simulate human TME in a 3D manner, including spheroids, organoids, and tumor‐on‐a‐chip, and their applications in basic cancer research, clinical use, and drug development. Created with BioRender.com.
Figure 1 Schematic overview showing the in vitro strategies to simulate human TME in a 3D manner, including spheroids, organoids, and tumor‐on‐a‐chip, and their applications in basic cancer research, clinical use, and drug development. Created with BioRender.com.CC BY-NC · PubMed Central
Figure 2 Schematic illustration of key components of the TME. TME is a highly complex system comprising cellular components and noncellular components, playing a critical role in cancer progression and evaluating therapy efficacy. Cellular components include heterogenous cancer cells, stromal cells (e.g., fibroblast, cancer‐associated fibroblast, etc.), endothelial cells, and diverse immune cells (macrophage, neutrophil, dendritic cell, etc.). Noncellular components include extracellular matrix, biochemical cues, and biophysical cues. Created with BioRender.com.
Figure 2 Schematic illustration of key components of the TME. TME is a highly complex system comprising cellular components and noncellular components, playing a critical role in cancer progression and evaluating therapy efficacy. Cellular components include heterogenous cancer cells, stromal cells (e.g., fibroblast, cancer‐associated fibroblast, etc.), endothelial cells, and diverse immune cells (macrophage, neutrophil, dendritic cell, etc.). Noncellular components include extracellular matrix, biochemical cues, and biophysical cues. Created with BioRender.com.CC BY-NC · PubMed Central
Figure 3 Spheroid models. a) PDMS‐based microwell arrays for culturing tumor spheroids to monitor the interactions among tumor spheroids, immune cells, and immune checkpoint inhibitors. Reproduced with permission.[ 58 ] Copyright 2021, Wiley‐VCH GmbH. b) Schematic illustration of the fabrication of hydrogel‐based microwell arrays for studying the effect of substrate composition and stiffness on tumor formation. Reproduced with permission.[ 60a ] Copyright 2017, IOP Publishing. c) Spheroids generated in a droplet‐based microfluidic platform for drug‐based cytotoxicity screening (p < 0.05). Reproduced with permission.[ 67 ] Copyright 2016, Royal Society of Chemistry. d) Hybrid hydrogel of collagen and alginate for fabrication of tumor spheroids for drug screening. Reproduced with permission.[ 72 ] Copyright 2017, American Chemical Society. e) Decellularized matrix for preparation of tumor spheroids for high‐throughput drug screening. Scalebars = 400 µm. Reproduced with permission.[ 78 ] Copyright 2021, Elsevier. f) Spheroids‐on‐a‐chip for studying the role of vascular perfusion in drug efficacy. Reproduced with permission.[ 81 ] Copyright 2020, Elsevier.
Figure 3 Spheroid models. a) PDMS‐based microwell arrays for culturing tumor spheroids to monitor the interactions among tumor spheroids, immune cells, and immune checkpoint inhibitors. Reproduced with permission.[ 58 ] Copyright 2021, Wiley‐VCH GmbH. b) Schematic illustration of the fabrication of hydrogel‐based microwell arrays for studying the effect of substrate composition and stiffness on tumor formation. Reproduced with permission.[ 60a ] Copyright 2017, IOP Publishing. c) Spheroids generated in a droplet‐based microfluidic platform for drug‐based cytotoxicity screening (p < 0.05). Reproduced with permission.[ 67 ] Copyright 2016, Royal Society of Chemistry. d) Hybrid hydrogel of collagen and alginate for fabrication of tumor spheroids for drug screening. Reproduced with permission.[ 72 ] Copyright 2017, American Chemical Society. e) Decellularized matrix for preparation of tumor spheroids for high‐throughput drug screening. Scalebars = 400 µm. Reproduced with permission.[ 78 ] Copyright 2021, Elsevier. f) Spheroids‐on‐a‐chip for studying the role of vascular perfusion in drug efficacy. Reproduced with permission.[ 81 ] Copyright 2020, Elsevier.CC BY-NC · PubMed Central
Figure 4 Organoid models. a) Schematic illustration of PDX‐derived tumor organoid encapsulated in enzymatically crosslinked HA‐Ph, gelatin‐Ph, or gelatin‐Ph/HA‐Ph hybrid hydrogels with tunable stiffness. Scale bars:100 µm. Reproduced with permission.[ 94 ] Copyright 2019, Elsevier. b) Schematics of ECM‐mimetic EKGel for growth of breast PDOs. Reproduced with permission.[ 96 ] Copyright 2022, Springer Nature. c) Microfluidic‐based organoid culture for drug sensitivity testing. Reproduced with permission.[ 103 ] Copyright 2019, Royal Society of Chemistry. d) Vascularized organoids chips for mimicking physiological delivery of drug to tumor sites. Scale bars:100 µm. Reproduced with permission.[ 104 ] Copyright 2019, Royal Society of Chemistry.
Figure 4 Organoid models. a) Schematic illustration of PDX‐derived tumor organoid encapsulated in enzymatically crosslinked HA‐Ph, gelatin‐Ph, or gelatin‐Ph/HA‐Ph hybrid hydrogels with tunable stiffness. Scale bars:100 µm. Reproduced with permission.[ 94 ] Copyright 2019, Elsevier. b) Schematics of ECM‐mimetic EKGel for growth of breast PDOs. Reproduced with permission.[ 96 ] Copyright 2022, Springer Nature. c) Microfluidic‐based organoid culture for drug sensitivity testing. Reproduced with permission.[ 103 ] Copyright 2019, Royal Society of Chemistry. d) Vascularized organoids chips for mimicking physiological delivery of drug to tumor sites. Scale bars:100 µm. Reproduced with permission.[ 104 ] Copyright 2019, Royal Society of Chemistry.CC BY-NC · PubMed Central
Figure 5 Microfluidic modeling of tumor metastasis. a) A microfluidic‐based platform for capturing vasculogenic and angiogenic vessel formation. Scale bars:100 µm. Reproduced with permission.[ 112 ] Copyright 2013, Royal Society of Chemistry. b) Microfluidic lumen‐based system for reconstituting angiogenesis in response to different proangiogenic factors. Scale bars:100 µm. Reproduced with permission.[ 114c ] Copyright 2013, National Academy of Sciences. c) Organotypic microfluidic device for investigating tumor invasion in the presence of CAFs. Reproduced with permission.[ 117 ] Copyright 2019, American Association for Cancer Research. d) Schematics of tumor‐immune microenvironment in vitro: tumor spheroids are cocultured with neutrophils separated by porous membrane. Reproduced with permission.[ 123 ]Copyright 2021, IOP Publishing. e) Hydrogel‐based microfluidic platform modeling tumor intravasation. Reproduced with permission.[ 127 ] Copyright 2012, National Academy of Sciences. f) A 3D vascularized microfluidic device replicating the effect of monocytes on tumor cell extravasation. Reproduced with permission.[ 128 ] Copyright 2018, Elsevier.
Figure 5 Microfluidic modeling of tumor metastasis. a) A microfluidic‐based platform for capturing vasculogenic and angiogenic vessel formation. Scale bars:100 µm. Reproduced with permission.[ 112 ] Copyright 2013, Royal Society of Chemistry. b) Microfluidic lumen‐based system for reconstituting angiogenesis in response to different proangiogenic factors. Scale bars:100 µm. Reproduced with permission.[ 114c ] Copyright 2013, National Academy of Sciences. c) Organotypic microfluidic device for investigating tumor invasion in the presence of CAFs. Reproduced with permission.[ 117 ] Copyright 2019, American Association for Cancer Research. d) Schematics of tumor‐immune microenvironment in vitro: tumor spheroids are cocultured with neutrophils separated by porous membrane. Reproduced with permission.[ 123 ]Copyright 2021, IOP Publishing. e) Hydrogel‐based microfluidic platform modeling tumor intravasation. Reproduced with permission.[ 127 ] Copyright 2012, National Academy of Sciences. f) A 3D vascularized microfluidic device replicating the effect of monocytes on tumor cell extravasation. Reproduced with permission.[ 128 ] Copyright 2018, Elsevier.CC BY-NC · PubMed Central
Figure 6 Microfluidic modeling of tumor response to therapeutics. a) Microfluidic invasion model that captures the crosstalk between tumor cells and CAFs for anticancer drug studies. Scale bar is 125 µm. Reproduced with permission.[ 135 ] Copyright 2017, Royal Society of Chemistry. b) Schematics of oxygen gradient‐array microfluidic device for studying the effect of oxygen levels on drug cytotoxicity in tumor spheroids. Reproduced with permission.[ 68a ] Copyright 2021, IOP Publishing. c) Illustration of microfluidic arrays to generate PDOs for developing personalized cancer therapies. Reproduced with permission.[ 106 ] Copyright 2021, Wiley‐VCH GmbH. d) Microfluidic lumen‐based system for evaluating anti‐angiogenesis treatment in RCC patients. Reproduced with permission.[ 138 ] Copyright 2019, Elsevier. e) Tumor‐vasculature‐on a‐chip for drug‐loaded nanoparticles evaluation. Reproduced with permission.[ 144 ] Copyright 2018, American Chemical Society. f) 3D microfluidic cancer angiogenesis‐on‐a‐chip for RNAi‐based nanomedicine evaluation. Scale bar is 200 µm. Reproduced with permission.[ 116 ] Copyright 2021, American Chemical Society.
Figure 6 Microfluidic modeling of tumor response to therapeutics. a) Microfluidic invasion model that captures the crosstalk between tumor cells and CAFs for anticancer drug studies. Scale bar is 125 µm. Reproduced with permission.[ 135 ] Copyright 2017, Royal Society of Chemistry. b) Schematics of oxygen gradient‐array microfluidic device for studying the effect of oxygen levels on drug cytotoxicity in tumor spheroids. Reproduced with permission.[ 68a ] Copyright 2021, IOP Publishing. c) Illustration of microfluidic arrays to generate PDOs for developing personalized cancer therapies. Reproduced with permission.[ 106 ] Copyright 2021, Wiley‐VCH GmbH. d) Microfluidic lumen‐based system for evaluating anti‐angiogenesis treatment in RCC patients. Reproduced with permission.[ 138 ] Copyright 2019, Elsevier. e) Tumor‐vasculature‐on a‐chip for drug‐loaded nanoparticles evaluation. Reproduced with permission.[ 144 ] Copyright 2018, American Chemical Society. f) 3D microfluidic cancer angiogenesis‐on‐a‐chip for RNAi‐based nanomedicine evaluation. Scale bar is 200 µm. Reproduced with permission.[ 116 ] Copyright 2021, American Chemical Society.CC BY-NC · PubMed Central
Figure 7 Microfluidic modeling of blood–brain barrier. a) A 3D neurovascular microfluidic model consisting of HUVECs, rat neurons and astrocytes. Reproduced with permission.[ 147 ] Copyright 2017, Royal Society of Chemistry. b) A low permeability microfluidic BBB platform incorporating vascular networks and rat neural cells (neurons and astrocytes). Reproduced with permission.[ 148 ] Copyright 2017, Springer Nature. c) Schematic representation of a microfluidic brain angiogenesis model containing human brain endothelial cells and human neural cells. Scale bar = 100 µm. Reproduced with permission.[ 151 ] Copyright 2019, Wiley. d) Schematic view of 3D BBB microvascular network model mimicking the microvascular structure present in the brain environment. Scale bars:100 µm. Reproduced with permission.[ 152 ] Copyright 2018, Elsevier. e) Schematics of a 3D in vitro BBB microvascular model to study brain metastasis. Reproduced with permission.[ 134 ] Copyright 2021, American Association for the Advancement of Science. f) Microfluidic lumen‐based BBB model to evaluate drug response of GBM spheroids. Reproduced with permission.[ 159 ]Copyright 2021, Wiley‐VCH GmbH.
Figure 7 Microfluidic modeling of blood–brain barrier. a) A 3D neurovascular microfluidic model consisting of HUVECs, rat neurons and astrocytes. Reproduced with permission.[ 147 ] Copyright 2017, Royal Society of Chemistry. b) A low permeability microfluidic BBB platform incorporating vascular networks and rat neural cells (neurons and astrocytes). Reproduced with permission.[ 148 ] Copyright 2017, Springer Nature. c) Schematic representation of a microfluidic brain angiogenesis model containing human brain endothelial cells and human neural cells. Scale bar = 100 µm. Reproduced with permission.[ 151 ] Copyright 2019, Wiley. d) Schematic view of 3D BBB microvascular network model mimicking the microvascular structure present in the brain environment. Scale bars:100 µm. Reproduced with permission.[ 152 ] Copyright 2018, Elsevier. e) Schematics of a 3D in vitro BBB microvascular model to study brain metastasis. Reproduced with permission.[ 134 ] Copyright 2021, American Association for the Advancement of Science. f) Microfluidic lumen‐based BBB model to evaluate drug response of GBM spheroids. Reproduced with permission.[ 159 ]Copyright 2021, Wiley‐VCH GmbH.CC BY-NC · PubMed Central

Verification

Claims the paper makes

23 Valid · 52 Not valid · 91 Not checked · 67 Own results and interpretations

133 more claims · 42 with their cited sources checked

Create a free account to see all 233 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 74
  • Probably not a substantial claim. 35

Create a free account to see these claims.

Citations

Cites

Show all 200 references

Research works printed but not linked: 7

  1. Mak I. W., 2014, Am. J. Transl. Res., 6, 114
  2. Bates D. O., 2002, Cancer Res., 62, 4123
  3. Subimerb C., 2010, Mol. Med. Rep., 3, 597
  4. Milosevic M., 2001, Cancer Res., 61, 6400
  5. 10.1371/journal.pone.0159013 · DOI · Paper page
  6. 10.1016/j.biomaterials.2018.07.048 · DOI · Paper page
  7. Sinha S., 2022, Adv. Healthcare Mater.

Cited by

See all 119

Metadata

Authors
Li, W., Zhou, Z., Zhou, X., Khoo, B. L., Gunawan, R., Chin, Y. R., Zhang, L., Yi, C., Guan, X., & Yang, M.
Affiliations
  • City University of Hong Kong (HK)
  • Sun Yat-sen University (CN)
  • Department of Clinical Oncology State Key Laboratory for Liver Research The University of Hong Kong Hong Kong SAR 999077 China
Corresponding author
Yang, Mengsu
Venue
Advanced Healthcare Materials
Publisher
Wiley
Published
2023-03-29
Volume
12
Issue
18
Pages
e2202609-e2202609
ISSN
  • 2192-2640 (ISSN-L)
  • 2192-2659
OpenAlex
W4324133297
Cited by
119
References
200
Citations by year
2026: 36 · 2025: 44 · 2024: 33 · 2023: 6
FWCI
2.51
Type
journal article
Language
en
Open access
Locations
  • Advanced Healthcare Materials (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
  • CityU Scholars (submittedVersion, cc-by-nc)
Funders
  • Impact Fund
  • City University of Hong Kong
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
tumor microenvironment, 3D tumor models, tumor spheroids, organoids, tumor-on-a-chip, biomimetic systems, hydrogels, microfluidics, preclinical drug screening, anticancer drug discovery, personalized medicine, animal-free model
MeSH terms
Animals, Neoplasms, Organoids, Spheroids, Cellular, Biomimetics, Lab-On-A-Chip Devices, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip. https://app.cochat.ai/papers/10.1002/adhm.202202609
The paper
Li, W., Zhou, Z., Zhou, X., Khoo, B. L., Gunawan, R., Chin, Y. R., Zhang, L., Yi, C., Guan, X., & Yang, M. (2023). 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202202609

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.